Pegcetacoplan structure
|
Common Name | Pegcetacoplan | ||
|---|---|---|---|---|
| CAS Number | 2019171-69-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | (C2H4O)nC170H248N50O47S4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PegcetacoplanPegcetacoplan is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acts effect by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia[1][2]. |
| Name | Pegcetacoplan |
|---|
| Description | Pegcetacoplan is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acts effect by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia[1][2]. |
|---|---|
| Related Catalog |
| Molecular Formula | (C2H4O)nC170H248N50O47S4 |
|---|